Pediatrix Director Files Intent to Sell $216K in Company Stock
Pediatrix Medical Group, Inc.
Subscribe to track MD
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Pediatrix Director Files Intent to Sell $216K in Stock
Company: Pediatrix Medical Group, Inc. (MD) Form: 144 | Filed: 2025-11-06 Significance: Low
Insider: Laura A Linynsky Title: Director | Relationship: Director
Transaction: • Type: Proposed Sale • Shares: 10,000 • Price: ~$21.62 • Value: $216,150 • Owned After: Not Disclosed
Key Insight: A director has filed a notice of a proposed sale of 10,000 shares. The transaction size is minor, representing just 0.012% of the company's market cap.
Market Context: This Form 144 filing signals an intent to sell and is considered a routine disclosure for insiders. Given its small size, it is unlikely to have a material impact on the stock.
Comprehensive Analysis
SEC Filing Analysis: Pediatrix Medical Group, Inc. (MD)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A director at Pediatrix Medical Group has filed a notice of proposed sale for 10,000 shares, a transaction with minimal financial scale relative to the company's size.
- Market Impact: Negligible market impact is expected due to the transaction's small value and share volume.
Company Information
| Field | Value |
|---|---|
| Company | Pediatrix Medical Group, Inc. |
| Ticker Symbol | MD |
| CIK | 0000893949 |
| Industry | Services-Hospitals |
Insider Information
| Field | Value |
|---|---|
| Name | Laura A Linynsky |
| CIK | 0001543891 |
| Title/Position | Director |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 |
| Transaction Date | 2025-11-06 (Approximate Sale Date) |
| Transaction Code | S (Proposed Sale) |
| Security Type | Common Stock |
| Shares Involved | 10,000 |
| Price Per Share | $21.615 (implied) |
| Total Value | $216,150 |
| Shares Owned After | Not Disclosed |
| Ownership Type | Not Disclosed |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $216,150 |
| % of Market Cap | 0.012% |
| Shares Transacted | 10,000 |
| % of Shares Outstanding | 0.011% |
| Post-Transaction Ownership | Not Disclosed |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The $216,150 proposed sale is insignificant compared to Pediatrix's $1.86 billion market capitalization.
- Ownership Concentration: Without post-transaction ownership data, it's impossible to assess the sale's impact on the insider's holdings, but the number of shares sold is a very small fraction of the total shares outstanding.
- Transaction Significance: The sale represents just 0.012% of the market cap and 0.011% of shares outstanding, placing it well below any threshold for material significance. This is considered a routine, non-impactful transaction.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The transaction is too small to signal any meaningful information or to affect supply/demand dynamics for the stock. It is a routine filing of intent to sell.
Volume & Sentiment
- Expected Volume Impact: Minimal. The 10,000 shares can likely be absorbed by the market with no noticeable impact on trading volume.
- Sentiment Indicator: Neutral. A small sale by a director is common for personal financial management and does not typically carry a strong market signal.
Additional Context
Transaction Notes
- This Form 144 is a notice of proposed sale, meaning the sale is intended to happen on or around the approximate sale date but has not yet been executed. The shares to be sold were originally acquired through stock plan activity.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
